Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in ...
Eisai and Biogen receive positive CHMP opinion for lecanemab, an Aβ monoclonal antibody for early Alzheimer's disease, with European Commission expected to make final decision within 67 days. Lecanemab targets soluble and insoluble Aβ aggregates, potentially reducing cognitive decline and improving daily living activities. The treatment is already approved in several countries and under review in 17 others.
EMA gives partial go-ahead for first Alzheimer's treatment in EU
EMA recommends EU approval of Leqembi, the first Alzheimer’s treatment that slows disease progression, for patients with one or no ApoE4 gene copy. The treatment, made by Eisai and Biogen, was previously rejected due to high side effect risks.
EU regulator backs Eisai-Biogen Alzheimer's drug
EU drugs regulator recommends Eisai and Biogen’s Leqembi for early Alzheimer’s patients with one or no ApoE4 gene variant, reversing earlier rejection due to brain swelling risks.
Leqembi Secures EMA Thumbs Up For Narrower Indication
EMA approves Eisai/Biogen's Alzheimer's drug Leqembi after initial rejection, with recommendations for initial generic screening and ongoing safety monitoring.
Eisai wins over European regulators on Alzheimer's drug Leqembi
EMA now supports Leqembi approval in Europe for mild Alzheimer’s patients with low ARIA risk, reversing earlier safety concerns. This decision could boost sales, with 20% from Europe, despite potential reimbursement hurdles and lower pricing.
European Watchdog Partially Approves New Alzheimer's Drug
Europe's EMA partially approves Leqembi for mild Alzheimer's, limited to patients with one or no ApoE4 gene copy, due to lower risk of brain bleeding.
Everything you need to know about NICE's decisions on 'game-changing' Alzheimer's drugs
NICE declined to recommend lecanemab and donanemab, new monoclonal antibody treatments for Alzheimer’s disease, in draft guidelines due to high costs and concerning side effects, despite MHRA licensing them for early-stage AD patients with no or one copy of the ApoE4 gene.
Eisai-Biogen's Alzheimer's Drug Lecanemab Wins Key EU Panel Backing After Appeal
Eisai and Biogen receive positive CHMP opinion for lecanemab, an Aβ monoclonal antibody for early Alzheimer's disease, with the European Commission expected to make a final decision on its marketing authorization within 67 days.
© Copyright 2024. All Rights Reserved by MedPath